Press release
Pneumococcal Infections Clinical Trial Pipeline Shows Potential with Active Contributions from 15+ Key Companies | DelveInsight
Discover the latest drugs and treatment options in the Pneumococcal infections Pipeline @ https://www.delveinsight.com/sample-request/pneumococcal-infections-pipeline-insight [https://www.delveinsight.com/sample-request/pneumococcal-infections-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Pneumococcal infections Pipeline Report
* In March 2026- Merck Sharp & Dohme LLC initiated a study is to evaluate the safety, tolerability, and immunogenicity of V116 compared to PPSV23 in children and teenagers 2 through 17 years of age, who had completed routine pneumococcal vaccine as infants/toddlers. Researchers want to learn if V116 is as good as, or is better than the PPSV23 vaccine in terms of the antibody immune response. V116 and PPSV23 will be studied in children and teenagers who have a higher risk of getting pneumococcal disease (PD).
* In March 2026- Pfizer conducted a phase 2 study is to learn about the safety, tolerability and immune effects of a pneumococcal vaccine in toddlers. Participants will take part in this study for approximately 6 or 8 months depending on which group they are assigned to. During this time participants will have 2 clinic visits and 1 phone visit for the 1-Dose group, or 3 clinic visits and 1 phone visit for the 2-Dose group.
* DelveInsight's Pneumococcal infections pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for Pneumococcal infections treatment.
* The leading Pneumococcal infections Companies such as GlaxoSmithKline, Gangagen, CanSino Biologics Inc., Pfizer, Merck Sharp & Dohme, EuBiologics, Beijing Zhifei Lvzhu Biopharmaceutical, SK Chemicals Co., Ltd., LG Life Sciences, Astellas Pharma, Affinivax, ImmunoBiology, Panacea Biotech, SutroVax, Vaxcyte and others.
* Promising Pneumococcal infections Pipeline Therapies such as V116, PCV15, PPSV23, Sinovac PCV24, V110, V114, Polysaccharide, PPSV23 and others.
Stay ahead with the most recent pipeline outlook for Pneumococcal infections @ Pneumococcal infections Treatment Drugs [https://www.delveinsight.com/sample-request/pneumococcal-infections-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Pneumococcal infections Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Pneumococcal infections Pipeline Report also highlights the unmet needs with respect to the Pneumococcal infections.
Pneumococcal infections Overview
Pneumococcal infections are caused by Streptococcus pneumoniae, a gram-positive, catalase-negative organism commonly referred to as pneumococcus. The bacteria spread through contact with people who are ill or by healthy people who carry the bacteria in the back of their nose. Pneumococcal infections can be mild or severe. Symptoms of pneumococcal infections vary depending on the site of the infection. Most pneumococcal infections occur in the Lungs (pneumonia), Middle ear (otitis media, which is common among children), Sinuses (sinusitis) Pneumococcal infections usually fall into one of two categories: non-invasive pneumococcal infections - these occur outside the major organs or the blood and tend to be less serious and invasive pneumococcal infections - these occur inside a major organ or the blood and tend to be more serious. People with a weakened immune system are most at risk of catching a pneumococcal infection. Diagnosis is based on the physical exam and medical history. Treatment is with antibiotics and vaccines that can prevent pneumococcal infections.
Pneumococcal infections Emerging Drugs Profile
* ASP3772: Affinivax
ASP3772 is designed to elicit both B-cell (antibody) and T-cell immune protection against Streptococcus pneumoniae. ASP3772 includes 24 pneumococcal polysaccharides, as well as two conserved pneumococcal proteins. The results from the Phase II clinical trial demonstrated that ASP3772 was well tolerated. ASP3772 also exhibited an antibody response to each of the 24 polysaccharides, as well as an additional antibody response to the conserved pneumococcal proteins. The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for ASP3772 for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes included in ASP3772 in adults aged 50 years and older. The FDA decision is informed by the results of the Phase 2 clinical data. The FDA's Breakthrough Therapy process is designed to expedite the development and review of drugs that are intended to treat a serious or life-threatening condition.
The Pneumococcal infections Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Pneumococcal infections with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pneumococcal infections Treatment.
* Pneumococcal infections Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Pneumococcal infections Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pneumococcal infections market
Explore groundbreaking therapies and clinical trials in the Pneumococcal infections Pipeline @ New Pneumococcal infections Drugs [https://www.delveinsight.com/sample-request/pneumococcal-infections-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Pneumococcal infections Companies
GlaxoSmithKline, Gangagen, CanSino Biologics Inc., Pfizer, Merck Sharp & Dohme, EuBiologics, Beijing Zhifei Lvzhu Biopharmaceutical, SK Chemicals Co., Ltd., LG Life Sciences, Astellas Pharma, Affinivax, ImmunoBiology, Panacea Biotech, SutroVax, Vaxcyte and others.
Pneumococcal infections Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intranasal
* Intrathecal
* Intravenous
* Oral
* Oral/Intravenous
* Parenteral
* Subcutaneous
* Subcutaneous/Intramuscular
* Transdermal
Pneumococcal infections Products have been categorized under various Molecule types such as
* Antisense oligonucleotide
* Gene therapy
* Hormones
* Neuropeptides
* Oligonucleotides
* Small Molecule
* Triglyceride
Learn about new drugs, pipeline developments with DelveInsight's expert analysis @ Pneumococcal infections Market Drivers and Barriers [https://www.delveinsight.com/sample-request/pneumococcal-infections-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Pneumococcal infections Pipeline Report
* Coverage- Global
* Pneumococcal infections Companies- GlaxoSmithKline, Gangagen, CanSino Biologics Inc., Pfizer, Merck Sharp & Dohme, EuBiologics, Beijing Zhifei Lvzhu Biopharmaceutical, SK Chemicals Co., Ltd., LG Life Sciences, Astellas Pharma, Affinivax, ImmunoBiology, Panacea Biotech, SutroVax, Vaxcyte and others.
* Pneumococcal infections Pipeline Therapies such as V116, PCV15, PPSV23, Sinovac PCV24, V110, V114, Polysaccharide, PPSV23 and others.
* Pneumococcal infections Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Pneumococcal infections Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Pneumococcal infections Therapies and clinical trials @ Pneumococcal infections Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/pneumococcal-infections-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Pneumococcal infections: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Pneumococcal infections- DelveInsight's Analytical Perspective
* Mid Stage Products (Phase III)
* Ceftobiprole medocaril: Basilea Pharmaceutica
* Mid Stage Products (Phase II)
* ASP3772: Affinivax
* Early Stage Products (Phase I/II)
* Pneumococcal vaccine conjugate 10-valent: Panacea Biotech
* Early Stage Products (Phase I)
* Pneumococcal conjugate vaccine: EuBiologics
* Preclinical Stage Products
* VAX XP: Vaxcyte
* Inactive Products
* Pneumococcal infections Key Companies
* Pneumococcal infections Key Products
* Pneumococcal infections- Unmet Needs
* Pneumococcal infections- Market Drivers and Barriers
* Pneumococcal infections- Future Perspectives and Conclusion
* Pneumococcal infections Analyst Views
* Pneumococcal infections Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=pneumococcal-infections-clinical-trial-pipeline-shows-potential-with-active-contributions-from-15-key-companies-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/pneumococcal-infections-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pneumococcal Infections Clinical Trial Pipeline Shows Potential with Active Contributions from 15+ Key Companies | DelveInsight here
News-ID: 4463112 • Views: …
More Releases from ABNewswire
Naperville's Trusted Choice for Garage Door Installation, Replacement & 24/7 Eme …
Aladdin Doors proudly serves Naperville, IL with professional garage door installation, garage door replacement, and emergency garage door repair services. Specializing in residential openers and commercial openers, the company delivers reliable, secure, and energy-efficient garage door solutions for homes and businesses. With expert technicians and a commitment to quality craftsmanship, Aladdin Doors ensures every project is completed safely and efficiently.
Reliable Garage Door Solutions Start with the Right Team
Your garage door…
Service Plus Garage Doors LLC Expands Reliable Garage Door Repair and Installati …
Service Plus Garage Doors LLC continues to strengthen its reputation in Seymour, Tennessee by delivering expert garage door repair, garage door installation, and maintenance services. With a focus on quality craftsmanship and customer satisfaction, the company offers comprehensive solutions for residential properties and commercial doors.
Trusted Garage Door Repair Services in Seymour, TN
Service Plus Garage Doors LLC [https://serviceplusgaragedoors.com/] is proud to deliver dependable garage door repair services to homeowners and businesses…
CoreAge Rx Earns Strong Trustpilot and BBB Recognition, Highlighting Consistent …
Independent reviews and patient feedback underscore CoreAge Rx's commitment to accessibility, transparency, and a structured weight management journey.
Image: https://www.abnewswire.com/upload/2026/04/c7616306ef1f45c44a6c041dfd8feef8.jpg
CoreAge Rx, a LegitScript-certified telehealth weight management provider based in Wichita Falls, Texas, is receiving strong recognition across leading review platforms and independent evaluations, with consistent feedback pointing to a reliable, structured, and patient-focused experience. Positive reviews on Trustpilot and a transparent presence on the Better Business Bureau (BBB) reflect the company's…
Rhode Island's Navy Mom's Coffee & Tea Raises Awareness for Wounded Warrior Proj …
Navy Mom's Coffee & Tea, the Rhode Island-based specialty coffee and tea brand founded by a Navy mom whose son serves in the United States Navy, has placed donation buttons on its website for two of the nation's leading military support organizations - the Wounded Warrior Project and the Navy Safe Harbor Foundation. Visitors to navymomscoffee.com can donate directly to either organization with no purchase required.
Navy Mom's Coffee & Tea,…
More Releases for Pneumococcal
Invasive Pneumococcal Disease Market Massive Growth opportunity Ahead
Introduction
Invasive pneumococcal disease (IPD), caused by Streptococcus pneumoniae, remains one of the leading causes of serious illness and death worldwide. Manifesting as meningitis, bacteremia, and severe pneumonia, IPD poses the greatest risk to infants, elderly adults, and immunocompromised patients. Despite progress in immunization, the disease continues to cause a significant global burden, particularly in regions with limited vaccine access.
The Invasive Pneumococcal Disease Market is entering a transformative phase, fueled by…
Key Influencer in the Pneumococcal Vaccine Market 2025: Rising Prevalence Of Pne …
What combination of drivers is leading to accelerated growth in the pneumococcal vaccine market?
The escalating occurrence of pneumococcal infections is projected to boost the pneumococcal vaccine market's growth. Pneumococcal infections represent any condition triggered by the bacterium Streptococcus pneumoniae, also known as pneumococcus. This includes illnesses like pneumonia, bloodstream infections, ear infections, and sinus infections. The pneumococcal vaccine encourages the body to generate antibodies against these bacteria, thereby minimizing or…
Pneumococcal Vaccines Market - Preventing Pneumonia: Safeguarding Health with Pn …
Newark, New Castle, USA: The "Pneumococcal Vaccines Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Pneumococcal Vaccines Market: https://www.growthplusreports.com/report/pneumococcal-vaccines-market/7761
This latest report researches the industry structure, sales, revenue,…
Global To Invigorate The Intravenous Pneumococcal Vaccines Market
Pneumococcal vaccine is used to prevent infection caused by streptococcus pneumoniae bacteria. There are two types of pneumococcal vaccines: pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine.
The Centers for Disease Control and Prevention (CDC) recommends pneumococcal conjugate vaccine for all children younger than two years of age, all adults 65 years or older, and for people 2-64 years old with certain medical conditions. The CDC recommends pneumococcal polysaccharide vaccine for all…
Pneumococcal Vaccines Market Demands and Gross Margin 2027
"Industry analysis is a crucial step in the current competitive market space that helps identify the right target customers and accordingly provide tailored solutions for their business needs. Every aspect and unique challenges put up by the particular industry are carefully taken into consideration while formulating these solutions. It also takes into consideration various government reforms, competitive environment, customer behavior, existing and upcoming business models, and ever-evolving technological developments. Industry…
Pneumococcal Vaccine Report on Global Pneumococcal Vaccine Market Development, p …
Latest Survey on Pneumococcal Vaccine Market:
The Global Pneumococcal Vaccine market report value has been estimated considering the application and regional segments, market share, and size, while the forecast for each product type and application segment has been provided for the global markets. The Pneumococcal Vaccine report offers detailed profiles of the key players to bring out a clear view of the competitive landscape of the Pneumococcal Vaccine Outlook. It also…
